Anticancer research最新文献

{"title":"Key Therapeutic Agents for Thymic Carcinoma in Real-world Clinical Practice.","authors":"Akiko Tateishi, Yusuke Okuma, Yasushi Goto, Motoko Arakaki, Yukiko Shimoda Igawa, Masahiro Torasawa, Yuki Shinno, Tatsuya Yoshida, Hidehito Horinouchi, Noboru Yamamoto, Yuichiro Ohe","doi":"10.21873/anticanres.17376","DOIUrl":"https://doi.org/10.21873/anticanres.17376","url":null,"abstract":"<p><strong>Background/aim: </strong>Thymic carcinoma is a rare cancer with poor prognosis in unresectable cases. Treatment efficacy of carboplatin+paclitaxel (CP), lenvatinib, S-1, and sunitinib remains uncertain, with some patients experiencing increased post-treatment liver metastasis.</p><p><strong>Patients and methods: </strong>We performed a retrospective analysis of patients with metastatic thymic carcinoma who received chemotherapy between 2006 and 2023 at the National Cancer Center Hospital. We evaluated the clinical outcomes [progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), liver metastasis response rate (LMRR), and liver metastasis control rate (LMCR)] of CP, lenvatinib, S-1, and sunitinib.</p><p><strong>Results: </strong>A total of 178 patients were evaluated, with 78.1% having stage IV disease. Most patients had squamous cell carcinoma (85.4%), and 39 patients had liver metastases (21.9%). The most frequently administered treatments as 1^st-, 2^nd-, and 3^rd- line were CP (85.5%), S-1 (58.3%), and sunitinib (28.4%). The median PFS was 6.8, 9.4, 4.5, and 3.4 months in CP, lenvatinib, S-1, and sunitinib. CP showed an ORR of 41.6% and LMRR of 40.9%. The reverse response, in which only liver metastasis increased despite shrinkage of other lesions, was observed in lenvatinib (20%), S-1 (3.4%), and sunitinib (8.3%).</p><p><strong>Conclusion: </strong>CP and lenvatinib provided effective outcomes in metastatic thymic carcinoma, aligning with previous findings. S-1 and sunitinib also show clinical activity but with variable responses in liver metastases. These results highlight the importance of tailored treatment strategies, particularly for patients with liver involvement.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"44 12","pages":"5501-5513"},"PeriodicalIF":1.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142765712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of ABCG2 rs2231142(421C>A) Variant on the Clinical Outcomes of Patients With <i>EGFR</i>-mutated Non-small Cell Lung Cancer Treated With Gefitinib: A Comprehensive Meta-analysis.","authors":"Francisco Cezar Aquino DE Moraes, Maria Eduarda Cavalcanti Souza, Emanuele Rocha DA Silva, Michele Kreuz, Rommel Mario Rodriguez Burbano","doi":"10.21873/anticanres.17363","DOIUrl":"10.21873/anticanres.17363","url":null,"abstract":"<p><strong>Background/aim: </strong>Lung cancer accounts for the largest percentage of cancer deaths worldwide, with non-small cell lung cancer (NSCLC) being the predominant type. Gefitinib, an EGFR tyrosine kinase inhibitor (EGFR-TKI), has shown marked efficacy in NSCLC patients with an EGFR mutation. However, gefitinib resistance because of ABCG2 polymorphisms such as rs2231142(421C > A) might limit its clinical use.</p><p><strong>Patients and methods: </strong>This meta-analysis followed the PRISMA guidelines and investigated the impact of the ABCG2 rs2231142 variant on gefitinib treatment outcomes in patients with NSCLC, using the PECOS model for study selection.</p><p><strong>Results: </strong>A total of 585 NSCLC patients treated with gefitinib were assessed for the association between genetic variants of the ABC transporter genes, specifically the ABCG2 C421A polymorphism, and clinical outcomes. No association was found between the ABCG2 C421A polymorphism and response to gefitinib chemotherapy (p=0.653; I2=0%). Similarly, no correlation was observed with gefitinib-induced skin rash (p=0.161177; I²=0%), diarrhea (p=0.064441), hepatotoxicity (p=0.210916; I²=0%), or interstitial pneumonia (p=0.138937).</p><p><strong>Conclusion: </strong>The ABCG2 rs2231142 polymorphism plays a significant role in the clinical outcomes of patients with EGFR-mutated NSCLC treated with gefitinib, warranting further investigation to clarify its impact on treatment efficacy and patient safety.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"44 12","pages":"5361-5370"},"PeriodicalIF":1.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142765644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic Strategies in Neurocutaneous Melanocytosis.","authors":"Dipanjan Basu","doi":"10.21873/anticanres.17341","DOIUrl":"10.21873/anticanres.17341","url":null,"abstract":"<p><p>Neurocutaneous melanocytosis (NCM) is a rare, congenital condition primarily affecting children, characterized by large or giant congenital melanocytic nevi (L/GCMN) on the skin and pigmented lesions in the brain. The presence of pigmented lesions in the brain often leads to neurological symptoms like headaches, seizures, and hydrocephalus, typically manifesting before age two. Melanocytic lesions in the brain can range from benign melanocytosis to malignant melanoma. NCM is nearly always fatal if symptomatic, with a high risk of malignant transformation. Patients with larger skin nevi with neurological involvement tend to have a greater lifetime risk of malignancy. There is no specific treatment, and current therapies focus on palliative care, including surgery, radiation, and chemotherapy. Malignant transformation into melanoma requires aggressive treatments like surgery, radiation, and chemotherapy. Despite these approaches, outcomes remain poor, with no definitive cure for NCM. This study aims to review and critically evaluate the current therapeutic strategies for NCM while also exploring prospective avenues for developing specific and effective treatments. It aims to highlight recent advancements in the molecular understanding of NCM and examine how these insights may inform the development of novel therapeutic approaches. Additionally, the study will address the significant unmet medical needs associated with this rare and often fatal condition, emphasizing the importance of continued research and innovation in its management.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"44 12","pages":"5157-5167"},"PeriodicalIF":1.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142765705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Regulation of Tumor Growth and Invasion in Oral Squamous Cell Carcinoma by the Tumor Microenvironment Through the Enhancement of IGFBP-3 Expression.","authors":"Dokyeong Kim, Young Jin Park, Young Sun Hwang","doi":"10.21873/anticanres.17361","DOIUrl":"https://doi.org/10.21873/anticanres.17361","url":null,"abstract":"<p><strong>Background/aim: </strong>Accumulated evidence indicates that interactions among various stromal cells within the tumor microenvironment (TME) significantly influence cancer progression. Oral cancers not diagnosed at early stages are associated with low five-year survival rates, highlighting the need for substantial improvements in patient outcomes. Understanding the interactions between cancer cells and the tumor microenvironment is crucial for identifying methods and developing treatment strategies that more effectively inhibit tumor progression and metastasis.</p><p><strong>Materials and methods: </strong>This study investigated the roles of cancer-associated fibroblasts (CAFs) and THP-1 monocytes in tumor growth and invasion, observing changes in cancer biological characteristics through interactions with stromal cells. HSC2 oral squamous cell carcinoma (OSCC) cells were co-cultured with normal fibroblasts (NF), cancer-associated fibroblasts (CAF), or THP-1 cells. Changes in cancer cell invasion were investigated using Matrigel-coated transwell assays, collagen-based dermal equivalent assays, and in vivo mouse studies.</p><p><strong>Results: </strong>HSC2 cells co-cultured with CAFs or THP-1 exhibited increased invasion compared to those co-cultured with normal fibroblasts (NF) in the dermal equivalent. In a mouse gingival xenograft model, cancer cells co-implanted with CAFs or THP-1 showed significantly increased tumor growth compared to those co-implanted with NF. Micro-CT (μCT) analysis revealed significant alveolar bone resorption around the mandible in tumors grown with CAFs or THP-1 cells. Conditioned media (CM) from CAFs or THP-1 significantly increased HSC2 invasion and migration, an effect that was inhibited by the protein secretion inhibitor Brefeldin (BFA). Furthermore, QuantSeq 3' mRNA sequencing indicated increased expression of IGFBP3, closely associated with cancer invasion, in HSC2 cells co-cultured with CAFs or THP-1.</p><p><strong>Conclusion: </strong>These findings suggest that cancer cells enhance their invasive characteristics through close interactions with the surrounding stromal cells.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"44 12","pages":"5337-5349"},"PeriodicalIF":1.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142765635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigation of Effectiveness of Nowarta110 Against Murine Malignant Melanoma in an Implanted Animal Model.","authors":"Jon Sin, Matei Kiosea, Nicolae Kiosea, Khosrow Mahdavi, Ferre Akbarpour, Hong-An N Tran, B O Han, Ba X Hoang","doi":"10.21873/anticanres.17349","DOIUrl":"https://doi.org/10.21873/anticanres.17349","url":null,"abstract":"<p><strong>Background/aim: </strong>Melanoma is a prevalent and severe disease, making the development of new treatments essential. Nowata110 has demonstrated significant therapeutic efficacy in phase II clinical study against plantar warts. It has shown promising anti-cancer effects in both in vitro and in vivo studies using HPV-16 and HPV-18-induced cervical cancer models. This study evaluated the effectiveness of Nowarta110 in murine melanoma-implanted animals.</p><p><strong>Materials and methods: </strong>Nowata110 is a novel compound composed of colloidal silver and fig extract. Male and female immunodeficient C(Cg)-Cd 79 atm 1 (cre) and immunocompetent BALB/c mice were used. Murine melanoma cancer cells (B16-F10) were implanted subcutaneously in experimental animals. Once the top cross-sectional area of tumors reached a minimum of 5 mm2 and approximately 4 mm depth, mice were anesthetized and treated with Nowarta110 intravenously or intratumorally. Control mice received no treatment.</p><p><strong>Results: </strong>In non-treated immunodeficient mice, tumor growth progressed over five weeks, whereas Nowarta110-treated mice drastically reduced tumor volume until five weeks after treatment was initiated. Similarly, in untreated BALB/c mice, tumor growth persisted over five weeks. However, Nowarta110-treated mice exhibited a notable reduction in tumor size. Although intravenous administration of Nowarta110 did not result in complete tumor regression in immunodeficient mice, it did lead to reduced tumor growth. In BALB/c immunocompetent mice, intravenous treatment generally stalled tumor progression.</p><p><strong>Conclusion: </strong>Intratumoral and intravenous administration of Nowarta110 effectively treated murine melanoma in immunodeficient and immunocompetent mice. The Nowarta110 antitumoral efficacy was more pronounced in immunocompetent mice treated intravenously than immunodeficient mice. Clinical studies to examine the efficacy of Nowarta110 in human melanoma and skin cancers are warranted.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"44 12","pages":"5219-5224"},"PeriodicalIF":1.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142765658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mitochondrial Metabolism as a Potential Novel Therapeutic Target for Lung Adenocarcinoma.","authors":"Makoto Fujiwara, Takahiro Mimae, Kei Kushitani, Norifumi Tsubokawa, Yoshihiro Miyata, Yukio Takeshima, Morihito Okada","doi":"10.21873/anticanres.17352","DOIUrl":"https://doi.org/10.21873/anticanres.17352","url":null,"abstract":"<p><strong>Background/aim: </strong>Oxidative phosphorylation (OXPHOS) is implicated in cancer progression and metastasis. However, its role in lung adenocarcinoma (LUAD) is unknown. We assessed OXPHOS in LUAD cases and cell lines and investigated the effect of OXPHOS inhibition on LUAD cells.</p><p><strong>Materials and methods: </strong>The cases with high expression of OXPHOS-related genes and peroxisome proliferator-activated receptor gamma (PPAR-γ) were extracted using RNA-seq data from The Cancer Genome Atlas (TCGA) LUAD dataset and the clinicopathological features and survival were assessed. Resected LUAD specimens were stained for PPAR-γ. Real-time qPCR and western blot were used to examine the expression of OXPHOS- and glycolysis-related genes and proteins in four LUAD cell lines. Cell proliferation was evaluated in LUAD cells treated with OXPHOS inhibitors.</p><p><strong>Results: </strong>The TCGA database analysis revealed that cases with high OXPHOS or PPAR-γ expression had a worse prognosis (p=0.07 and p=0.01, respectively). High OXPHOS cases were associated with lymph node metastasis (p<0.01). PPAR-γ was expressed only in the peripheral area of the papillary component of LUAD. We identified A549, HTB181 and H322 as OXPHOS-high type cells and H596 as OXPHOS-low type cells. Oligomycin treatment inhibited cell proliferation in the OXHOS-high cells (0.72-, 0.69-, and 0.77- fold change in oligomycin vs. DMSO, for A549, HTB181, and H322 cells, respectively, p<0.01) but not in the OXPHOS-low cells.</p><p><strong>Conclusion: </strong>High expression of OXPHOS-related genes and PPAR-γ is a poor prognostic factor in LUAD. The levels of OXPHOS vary among cases and within different areas of the tumor. Targeting OXPHOS metabolism may represent a novel therapeutic approach for treating LUAD.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"44 12","pages":"5241-5252"},"PeriodicalIF":1.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142765699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perioperative Anemia Is an Independent Prognostic Factor for Gastric Cancer Patients Who Receive Curative Treatment.","authors":"Toru Aoyama, Itaru Hashimoto, Yukio Maezawa, Ryuki Esashi, Sosuke Yamamoto, Kiyoko Shimada, Keisuke Kazama, Koji Numata, Mamoru Uchiyama, Ayako Tamagawa, Aya Saito, Norio Yukawa","doi":"10.21873/anticanres.17381","DOIUrl":"https://doi.org/10.21873/anticanres.17381","url":null,"abstract":"<p><strong>Background/aim: </strong>This study evaluated the clinical impact of anemia during the perioperative period on both short- and long-term oncological outcomes in resectable gastric cancer (GC) patients who received curative treatment.</p><p><strong>Patients and methods: </strong>We conducted a retrospective review of medical records and collected data from consecutive patients with gastric cancer who underwent curative resection at Yokohama City University between 2015 and 2022.</p><p><strong>Results: </strong>A total of 330 patients were evaluated in this study. In the present study, we set the cutoff value of preoperative hemoglobin at 11.0 g/dl. The 1-, 3-, and 5-year overall survival rates were 88.6%, 59.8%, and 47.0%, respectively, in patients with hemoglobin levels <11 g/dl, and 96.8%, 86.0%, and 80.0% in those with hemoglobin levels ≥11 g/dl. Based on univariate and multivariate analyses, the preoperative hemoglobin status was identified as an independent prognostic factor for both overall survival (hazard ratio=1.772, 95% confidence interval=1.109-2.831, p=0.017) and recurrence-free survival (hazard ratio=1.782; 95% confidence interval=1.166-2.723, p=0.008). In addition, perioperative anemia was also found to affect the clinical course of postoperative surgical complications and postoperative adjuvant chemotherapy.</p><p><strong>Conclusion: </strong>Perioperative anemia was identified as an independent prognostic factor in GC patients who received curative treatment. To improve the survival of patients with GC, it is necessary to provide care and management for perioperative anemia before curative treatment.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"44 12","pages":"5551-5557"},"PeriodicalIF":1.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142765752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Multifaceted Role of Striatin-interacting Protein 2 (STRIP2) in Disease Pathogenesis and Cancer Progression.","authors":"Jaber H Jaradat, Ghaith Masharqa, Raneem Ghazi Al-Shnaikat, Maya Mashal, Ahmed M Al-Nusairi, Anwaar Saeed","doi":"10.21873/anticanres.17342","DOIUrl":"10.21873/anticanres.17342","url":null,"abstract":"<p><p>Striatin-interacting protein 2 (STRIP2), encoded by the STRIP2 gene, plays a critical role in various biological processes. It is an integral part of the striatin-interacting phosphatase and kinase (STRIPAK) complex and is involved in cell growth, proliferation, migration, and differentiation. In this review, we explored the multifaceted functions of STRIP2 across different cancers, including non-small cell lung cancer (NSCLC), breast cancer, colorectal cancer, prostate cancer, and others. We searched the PubMed database for studies investigating STRIP2 in tumors or pathological processes. Our search yielded 30 studies. After meticulous screening, only 14 studies were included in this review. Based on our results, STRIP2 is overexpressed and amplified in multiple cancer types, including NSCLC, breast cancer, colorectal cancer, and prostate cancer, and is associated with poor prognosis. In NSCLC, it promotes tumor progression through mechanisms involving mRNA stabilization, Akt/mTOR pathway, epithelial-mesenchymal transition (EMT), and immune regulation. In breast and colorectal cancers, elevated STRIP2 levels correlate with reduced overall survival. In prostate cancer, STRIP2 contributes to cell migration and cytoskeletal organization. Furthermore, interaction of STRIP2 with immune checkpoint genes suggests its role in tumor immune evasion, offering therapeutic potential for targeting the tumor microenvironment. We conclude that STRIP2 acts as an oncogene in various tumors and is associated with a poor prognosis. It is involved in critical oncogenic pathways including proliferation, EMT, and immune regulation, highlighting its potential as a therapeutic target. This review supports the importance of investigating the diagnostic, prognostic, and therapeutic role of STRIP2 in various cancers, particularly NSCLC.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"44 12","pages":"5169-5174"},"PeriodicalIF":1.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142765674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigenda.","authors":"","doi":"10.21873/anticanres.17386","DOIUrl":"https://doi.org/10.21873/anticanres.17386","url":null,"abstract":"","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"44 12","pages":"5591-5592"},"PeriodicalIF":1.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142765355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>LET-7a</i> and <i>LET-7b</i> as Potential Signatures for Glioma Recurrence, Regardless of WHO Tumor Grade.","authors":"Sylvie Weber, Saskia Kuhl, Roland Goldbrunner, Marco Timmer","doi":"10.21873/anticanres.17346","DOIUrl":"https://doi.org/10.21873/anticanres.17346","url":null,"abstract":"<p><strong>Background/aim: </strong>Micro RNAs (miRs; miRNAs) are small, non-coding RNA segments that influence gene expression. To do this, they bind to corresponding mRNA segments and inhibit the subsequent protein translation. Currently, about 200 transcripts are thought to be regulated by a single miRNA. Dysregulated miRNAs can act as tumor promoters as well as tumor suppressors. The aim of this study was to verify miR-LET-7a and miR-LET-7b as a signature for glioma recurrence detection by analyzing their expression in glioma tissue.</p><p><strong>Materials and methods: </strong>Only patients with two or more recurrences of glioma (n=25) were included in the study (tissue samples, n=89). Tissue was obtained during neurosurgical procedures and shock-frozen in liquid nitrogen. The patient cohort (female:male=12:13) had an average age of 35 years when first diagnosed (primary tumor: 13 WHO grade II, 7 WHO grade III and 5 WHO grade IV) and 48 years in the fifth relapse. Quantitative real-time polymerase chain reaction was performed to analyze miRNA expression. miR-151a-3p was used as an internal reference.</p><p><strong>Results: </strong>Expression of miR-LET-7a and miR-LET-7b was significantly lower in the first recurrence than in the primary tumor. The expression of miR-LET-7a and -7b significantly decreased with increasing tumor grade. The strongest down-regulation was found between WHO grade III and IV. In paired samples in which tumor grade did not change between the primary and the first recurrence, the expression of both miRNAs remained significantly lower in the recurrent than in the primary tumor.</p><p><strong>Conclusion: </strong>miR-LET-7a and miR-LET-7b represent a potential signature for glioma recurrence regardless of WHO grade.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"44 12","pages":"5199-5205"},"PeriodicalIF":1.6,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142765363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}